An official website of the United States government
Home
Name
Acalabrutinib
Alternate Names
Calquence
Abbreviations
None
Category
Chemotherapy
Subcategory
kinase inhibitor
NSC Number
None
Primary Site
None
Histology
Remarks
October 31, 2017: FDA has granted accelerated approval to Calquence (Acalabrutinib, previously known as ACP-196), a kinase inhibitor, for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
November 21, 2019 FDA approved acalabrutinib (CALQUENCE) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
November 21, 2019 FDA approved acalabrutinib (CALQUENCE) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Coding
This drug should be coded
